Trials / Recruiting
RecruitingNCT06949852
Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine for Postoperative Analgesia
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Nalbuphine Versus Morphine for the Treatment of Postoperative Analgesia
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 288 (estimated)
- Sponsor
- Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of safety and efficacy of Nalbuphine versus Morphine patient controlled intravenous analgesia (PCIA) for the treatment of postoperative analgesia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nalbuphine Hydrochloride Injection | PCIA，The lockout interval is set at 10 minutes, with no background infusion. |
| DRUG | Morphine Hydrochloride Injection | PCIA，The lockout interval is set at 10 minutes, with no background infusion. |
Timeline
- Start date
- 2024-08-07
- Primary completion
- 2025-06-01
- Completion
- 2026-03-01
- First posted
- 2025-04-29
- Last updated
- 2025-04-29
Locations
24 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06949852. Inclusion in this directory is not an endorsement.